[go: up one dir, main page]

ATE315028T1 - Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester - Google Patents

Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Info

Publication number
ATE315028T1
ATE315028T1 AT00310064T AT00310064T ATE315028T1 AT E315028 T1 ATE315028 T1 AT E315028T1 AT 00310064 T AT00310064 T AT 00310064T AT 00310064 T AT00310064 T AT 00310064T AT E315028 T1 ATE315028 T1 AT E315028T1
Authority
AT
Austria
Prior art keywords
trifluoromethyl
methoxycarbonylamino
quinoline
dihydro
benzyl
Prior art date
Application number
AT00310064T
Other languages
English (en)
Inventor
David Burns Damon
Robert Wayne Dugger
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Application granted granted Critical
Publication of ATE315028T1 publication Critical patent/ATE315028T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/38—Nitrogen atoms
    • C07D215/42—Nitrogen atoms attached in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Quinoline Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
AT00310064T 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester ATE315028T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US16796799P 1999-11-30 1999-11-30

Publications (1)

Publication Number Publication Date
ATE315028T1 true ATE315028T1 (de) 2006-02-15

Family

ID=22609556

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00310064T ATE315028T1 (de) 1999-11-30 2000-11-13 Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester

Country Status (44)

Country Link
US (1) US6313142B1 (de)
EP (1) EP1125929B1 (de)
JP (1) JP3579345B2 (de)
KR (1) KR100408177B1 (de)
CN (1) CN1173953C (de)
AP (1) AP2000002011A0 (de)
AR (1) AR029775A1 (de)
AT (1) ATE315028T1 (de)
AU (1) AU784694B2 (de)
BG (1) BG105009A (de)
BR (1) BR0005636A (de)
CA (1) CA2327029C (de)
CO (1) CO5261552A1 (de)
CY (1) CY1104989T1 (de)
CZ (1) CZ20004407A3 (de)
DE (1) DE60025317T2 (de)
DK (1) DK1125929T3 (de)
DZ (1) DZ3079A1 (de)
EA (1) EA003668B1 (de)
EE (1) EE200000659A (de)
ES (1) ES2254109T3 (de)
GE (1) GEP20022798B (de)
GT (1) GT200000190A (de)
HN (1) HN2000000203A (de)
HR (1) HRP20000804A2 (de)
HU (1) HUP0004747A3 (de)
ID (1) ID28489A (de)
IL (1) IL139849A (de)
IS (1) IS5715A (de)
MA (1) MA25223A1 (de)
NO (1) NO20006039L (de)
NZ (1) NZ508509A (de)
OA (1) OA11494A (de)
PA (1) PA8503801A1 (de)
PE (1) PE20010913A1 (de)
PL (1) PL344208A1 (de)
SG (1) SG102603A1 (de)
SK (1) SK17792000A3 (de)
TN (1) TNSN00230A1 (de)
TW (1) TW591016B (de)
UA (1) UA65615C2 (de)
UY (1) UY26451A1 (de)
YU (1) YU71500A (de)
ZA (1) ZA200006947B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.
WO2003053368A2 (en) * 2001-12-19 2003-07-03 Atherogenics, Inc. Chalcone derivatives and their use to treat diseases
US7202247B2 (en) 2001-12-19 2007-04-10 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
AU2003230916A1 (en) * 2002-04-11 2003-10-27 Roar Holding Llc Ex vivo method for determination of cetp activity and efficacy of heart disease treatment
US20090181966A1 (en) * 2002-10-04 2009-07-16 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7211672B2 (en) * 2002-10-04 2007-05-01 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7504508B2 (en) * 2002-10-04 2009-03-17 Millennium Pharmaceuticals, Inc. PGD2 receptor antagonists for the treatment of inflammatory diseases
US7223870B2 (en) 2002-11-01 2007-05-29 Pfizer Inc. Methods for preparing N-arylated oxazolidinones via a copper catalyzed cross coupling reaction
US20040181075A1 (en) * 2002-12-19 2004-09-16 Weingarten M. David Process of making chalcone derivatives
US20040132771A1 (en) * 2002-12-20 2004-07-08 Pfizer Inc Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors
MXPA05005813A (es) 2002-12-20 2005-12-12 Pfizer Prod Inc Formas de dosificacion que comprenden un inhibidor de la cetp y un inhibidor de la hmg-coa reductasa.
JP2006523218A (ja) * 2003-03-04 2006-10-12 高砂香料工業株式会社 光学活性アミン類の製造方法
AU2004222436A1 (en) * 2003-03-17 2004-09-30 Japan Tobacco Inc. Method for increasing the oral bioavailability of S-(2-(((1- (2-ethylbutyl) cyclohexyl)carbonyl) amino) phenyl)-2-methylpropanethioate
NZ542852A (en) * 2003-03-17 2008-09-26 Japan Tobacco Inc Pharmaceutical compositions of CETP inhibitors
TWI494102B (zh) * 2003-05-02 2015-08-01 Japan Tobacco Inc 包含ｓ-〔２（〔〔１-（２-乙基丁基）環己基〕羰基〕胺基）苯基〕２-甲基丙烷硫酯及ｈｍｇ輔酶ａ還原酶抑制劑之組合
CN1863778A (zh) * 2003-10-08 2006-11-15 伊莱利利公司 用于治疗血脂异常的化合物及方法
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
EA200700119A1 (ru) * 2004-06-24 2007-10-26 Эли Лилли Энд Компани Соединения и способы лечения дислипидемии
DOP2005000123A (es) * 2004-07-02 2011-07-15 Merck Sharp & Dohme Inhibidores de cetp
WO2006033001A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Quinoline compounds
US7700774B2 (en) * 2004-12-20 2010-04-20 Dr. Reddy's Laboratories Ltd. Heterocyclic compounds and their pharmaceutical compositions
WO2006091674A1 (en) * 2005-02-24 2006-08-31 Millennium Pharmaceuticals, Inc. Pgd2 receptor antagonists for the treatment of inflammatory diseases
TW200808731A (en) 2006-03-30 2008-02-16 Tanabe Seiyaku Co A process for preparing tetrahydroquinoline derivatives
EP2134169A2 (de) 2007-03-09 2009-12-23 Indigene Pharmaceuticals Inc. Kombination von metformid-r-(+)-lipoat und antihyperlipidämika für die behandlung von diabetes-hyperglykämie und diabetesbedingte komplikationen
CN101429160B (zh) * 2007-11-06 2011-10-19 上海药明康德新药开发有限公司 一种1-r-4-氨基-1,2,3,4-四氢喹啉的合成方法
TWI450896B (zh) 2009-06-30 2014-09-01 Lilly Co Eli 反式－４－〔〔（５ｓ）－５－〔〔〔３，５－雙（三氟甲基）苯基〕甲基〕（２－甲基－２ｈ－四唑－５－基）胺基〕－２，３，４，５－四氫－７，９－二甲基－１ｈ－１－苯并氮呯－１－基〕甲基〕－環己基羧酸
TW202409008A (zh) 2022-07-05 2024-03-01 荷蘭商新阿姆斯特丹製藥公司 奧比特拉(obicetrapib)鹽及彼等之製造方法與中間體

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR7870M (de) * 1968-11-08 1970-04-27
US3971789A (en) 1972-10-21 1976-07-27 John Wyeth & Brother Limited O-(4-Quinolylamino)benzamides
GB8432091D0 (en) 1984-12-19 1985-01-30 Wyeth John & Brother Ltd 4-aminoquinoline derivatives
US4839368A (en) 1986-05-02 1989-06-13 Mochida Pharmaceutical Co., Ltd. 1-acyl-2,3-dihydro-4(1H)-quinolinone-4-oxime derivatives
GB8804444D0 (en) 1988-02-25 1988-03-23 Smithkline Beckman Intercredit Compounds
US5231102A (en) 1989-03-08 1993-07-27 Merck Sharp & Dohme, Ltd. Tetrahydroquinoline derivatives useful for neurodegenerative disorders
PT100905A (pt) * 1991-09-30 1994-02-28 Eisai Co Ltd Compostos heterociclicos azotados biciclicos contendo aneis de benzeno, ciclo-hexano ou piridina e de pirimidina, piridina ou imidazol substituidos e composicoes farmaceuticas que os contem
US6147089A (en) 1998-09-17 2000-11-14 Pfizer Inc. Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines
US6197786B1 (en) * 1998-09-17 2001-03-06 Pfizer Inc 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines
US6140342A (en) 1998-09-17 2000-10-31 Pfizer Inc. Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines
HN2000000203A (es) * 1999-11-30 2001-06-13 Pfizer Prod Inc Procedimiento para la obtencion de 1,2,3,4-tetrahidroquinolinas 4-carboxiamino-2- sustituidas.

Also Published As

Publication number Publication date
DE60025317D1 (de) 2006-03-30
ZA200006947B (en) 2002-05-27
ES2254109T3 (es) 2006-06-16
DZ3079A1 (fr) 2004-10-24
BG105009A (en) 2001-11-30
SG102603A1 (en) 2004-03-26
EA003668B1 (ru) 2003-08-28
UY26451A1 (es) 2001-06-29
AR029775A1 (es) 2003-07-16
IS5715A (is) 2001-05-31
PA8503801A1 (es) 2002-07-30
SK17792000A3 (sk) 2002-10-08
CY1104989T1 (el) 2010-03-03
EA200001129A3 (ru) 2001-10-22
PE20010913A1 (es) 2001-09-10
UA65615C2 (uk) 2004-04-15
DK1125929T3 (da) 2006-04-03
HRP20000804A2 (en) 2001-06-30
JP3579345B2 (ja) 2004-10-20
PL344208A1 (en) 2001-06-04
US6313142B1 (en) 2001-11-06
MA25223A1 (fr) 2001-07-02
AU784694B2 (en) 2006-06-01
GEP20022798B (en) 2002-09-25
TW591016B (en) 2004-06-11
TNSN00230A1 (fr) 2005-11-10
CO5261552A1 (es) 2003-03-31
NO20006039D0 (no) 2000-11-29
CA2327029A1 (en) 2001-05-30
YU71500A (sh) 2003-02-28
CA2327029C (en) 2005-08-09
EE200000659A (et) 2001-08-15
HU0004747D0 (de) 2001-02-28
EA200001129A2 (ru) 2001-06-25
IL139849A (en) 2006-10-31
CN1302800A (zh) 2001-07-11
KR20010052012A (ko) 2001-06-25
EP1125929B1 (de) 2006-01-04
AU7178900A (en) 2001-05-31
KR100408177B1 (ko) 2003-12-01
IL139849A0 (en) 2002-02-10
ID28489A (id) 2001-05-31
CZ20004407A3 (cs) 2002-06-12
CN1173953C (zh) 2004-11-03
OA11494A (en) 2004-05-07
AP2000002011A0 (en) 2000-12-31
HUP0004747A2 (hu) 2001-10-28
NO20006039L (no) 2001-05-31
HN2000000203A (es) 2001-06-13
HUP0004747A3 (en) 2002-12-28
GT200000190A (es) 2002-04-27
BR0005636A (pt) 2001-07-17
EP1125929A1 (de) 2001-08-22
JP2001163859A (ja) 2001-06-19
DE60025317T2 (de) 2006-08-03
HK1038007A1 (en) 2002-03-01
NZ508509A (en) 2001-06-29

Similar Documents

Publication Publication Date Title
ATE315028T1 (de) Herstellungsverfahren für (-)-(2r,4s)-4-((3,5-bis-trifluoromethyl-benzyl) methoxycarbonylamino)-2- ethyl-6-trifluoromethyl-3,4-dihydro-2h-chinolin 1-carbonylsäureethylester
DE69930317D1 (de) Verfahren zur verhinderung von physiologischen störungen ohne die photosynthese zu vermindern
ATE258927T1 (de) Verbessertes verfahren zur herstellung von n- substituierte aminotetraline
DE60200412D1 (de) Polyhydroxyalkanoat und Verfahren zu dessen Herstellung, und Omega-(2-Thienylsulfanyl)alkansäure und Verfahren zu deren Herstellung
NO20035613D0 (no) Fremgangsmåte for naftaavsvovling
AR024800A1 (es) Proceso de produccion de fenil-alcanos
DE60010616D1 (de) Wasserdispergierbares Faserflächenprodukt und Verfahren zu seiner Herstellung
DE69834562D1 (de) Verfahren für die produktion von malonsäure-derivaten.
DE60018531D1 (de) Oxydkomplex als Katalysator und Verfahren für die Herstellung von Acrylsäure
DE60005870D1 (de) Verfahren zur Herstellung von Acrylsäure
DE69833200D1 (de) Verfahren für die produktion von l-glutaminsäure mittels fermentation
DE60124296D1 (de) Biphenylcarbonsäureamide, die sich als lipidsenker eignen
DE60017941D1 (de) Benzoesäureester von oxazolidinonen, die hydroxyacetylpiperazin-gruppen tragen
ID24863A (id) Proses pembuatan vinil ester dari butenoligomeran
DE69706903D1 (de) Verfahren für die Herstellung von Mercaptanen
ID28447A (id) Proses polimerisasi kontinu pembuatan poliamida-poliamida dari omega-aminonitril
ITMI20001543A0 (it) Spray scintillante per biancheria
ID26278A (id) Proses pembuatan sertralina dari kiral tetralon
DE60205502D1 (de) Verfahren zur herstellung von alpha-hydroxycarbonsäureamiden
DE60004072D1 (de) Verfahren für die Herstellung von Lacton
DE60135395D1 (de) Prozess für die Herstellung von (Meth)acrylsäureanhydrid
DE60113323D1 (de) Verfahren für die Herstellung von L-Phenylalanin
ATE401299T1 (de) Verfahren für die herstellung von hydroxyethylaminen
DE60125941D1 (de) Elektrochemischer Kondensator und Verfahren zu seiner Herstellung
ATE264829T1 (de) Verfahren zur herstellung von acylierten 1,3- dicarbonylverbindungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1125929

Country of ref document: EP

REN Ceased due to non-payment of the annual fee